Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 71205-557

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71205-557). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
The image depicts a graph showing the estimated probability of achieving a headache response within 2 hours of treatment with rizatriptan benzoate or placebo. The data presented in the graph is obtained by pooling data from four outpatient trials showing evidence of efficacy. The graph shows the Kaplan-Meier plot of the probability over time. Patients who did not achieve a headache response within 2 hours or were taking additional treatment were censored at 2 hours.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)
This is a figure depicting the estimated probability of patients taking a second dose of Rizatriptan Benzoate orally disintegrating tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled studies 5 and 6. The plot provides a Kaplan-Mier estimation based on data obtained in 2 placebo-controlled outpatient clinical trials (Studies 3 and 6). Patients not using additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who had no response to the initial dose. The figure displays the estimated probability of remedication or rescue over the 24-hour period.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
The image shows observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7, represented graphically. The graph includes two lines: one for Rizatriptan Benzoate OD Tablets and the other for Placebo. The X-axis indicates Hours Post Stage 2 Dose, and the Y-axis shows the percentage of patients (with values ranging from 0% to 100%) reporting no headache pain. There is a key showing that the line with circles represents the placebo and the line with dashes represents Rizatriptan Benzoate OD Tablets.*
FDA Label Image

71205-557-06 (Rizatriptan Fig7)

71205-557-06 (Rizatriptan Fig7)
This is a medication named Rizatriptan Benzoate ODT 10mg. It is available in a pack of 1X6 orally disintegrating tablets. Each tablet contains 14.53 mg of rizatriptan benzoate, equivalent to 10 mg of rizatriptan. The tablets are white to off-white, circular, biconvex, uncoated with F25' debossed on one side and plain on the other side with a peppermint flavor. It is distributed by Rising Health LLC, Saddle Brook, NJ, and manufactured in India. The medication must be stored at 20°-25°C (68°77°F) and kept out of reach of children. It is relabeled by Proficient Rx LP, Thousand Oaks, CA. Different lots have different SN# MASTER, Exp. 00/00/00, and NDC codes. GTIN: 0037120557065.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.